wushuang 发布
赢润生物首席科学家Ian Lee Alberts（李白）博士成功入选湖南省“百人计划”并直接纳入长沙市2011年第一批“313计划”，这是我司通过“百人计划”和“313计划”从海外引进的第一位高层次人才。
湖南“百人计划”是按照中央统一部署，从2009年起启动实施了引进海外高层次人的一项战略举措，计划用5年左右时间，引进100名左右海外高层次人才。2009年长沙出台了《长沙市引进国际高端人才三年行动计划（2009—2011年）》（简称“313计划”）。计划从2009年起，长沙市委、市政府决定用三年时间，引进100名高端人才，30个高端人才团队。主要引进长沙产业经济发展急需的、应用型和关键性的高端技术人才、高层管理人才和高级金融人才，特别是重点引进由高端人才率领的创新专业研发和管理团队。长沙市为此专门设立了国际高端人才专项资金。凡长沙市范围内的用人单位引进一名高端人才或由高端人才率领的团队，入选“313计划”的，由市财政向用人单位拨付100万元，用于为引进的国际高端人才提供安家费补助和事业启动资金，同时享受收入所得税返还等一系列优惠政策。
李白博士简介
Dr. Ian L. Alberts graduated from the University of Cambridge, UK in 1988, where he was awarded his Ph.D. in Theoretical Chemistry. Since then, he has over 20 years experience working in the area of Computational Chemistry in both industrial and academic institutions. His research work has focused on the development and application of state-of-the-art methodology for Computational Drug Discovery.
Dr. Alberts has made key contributions in many drug discovery projects, involving hit identification and the optimization of lead series of compounds. He has been the primary modeler on several projects that successfully designed active hit compounds and achieved milestones. These studies entailed application of many computational techniques, including structure-based design, ligand-based design, fragment-based design, virtual high-throughput screening, scaffold hopping, ADME-Tox profiling, QSAR model development and protein structure prediction. Dr. Alberts has extensive experience in designing ligands for many targets of therapeutic interest, such as, kinases, matrix metalloproteases, metabolic enzymes, GPCRs, synthetases, and DNA polymerases. He has also explored a diverse range of novel, lead chemotypes for these systems. These projects have involved close collaborations with in-house and external medicinal chemists, synthetic chemists, pharmacologists, crystallographers and biologists.
Dr. Alberts has developed and pioneered several innovative Computer-Aided Drug Design procedures, for example (i) incorporation of protein flexibility in fragment-based de novo design, ligand docking and high throughput virtual screening, (ii) site of metabolism prediction in substrates of cytochrome P450 enzymes, (iii) design of ligands that are specific for selected protein sub-families.
Dr. Alberts has extensive experience in the utilization of many molecular modeling software packages, as well as a solid background in medicinal and synthetic organic chemistry. He has authored numerous reviews and publications, and regularly presents his work at international, scientific conferences.